• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

    3/19/25 12:45:00 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRN alert in real time by email

    Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with certain of their affiliates, the "Concerned Shareholder Group" or "we"), who collectively own approximately 15 million shares of Amarin Corporation plc (NASDAQ:AMRN) ("Amarin" or the "Company"), today issued the following open letter to the Company's Board of Directors.

    ***

    Amarin Corporation plc

    ATTN: Board of Directors (the "Board")

    88 Harcourt Street

    Dublin 2, Ireland

    Members of the Board,

    We are meaningful shareholders of Amarin. While we appreciate Sarissa Capital Management's ("Sarissa") involvement and commitment to the Company, we believe shareholders would be best served by the Board immediately conducting a strategic review to maximize shareholder value.

    In February 2023, Amarin's share price traded at $2.03 after shareholders supported Sarissa's plan to unlock shareholder value by voting to elect its director candidates.1 Shortly after the 2023 General Meeting, the reconstituted Board stated that it "had begun the hard work of creating value for shareholders" and expressed confidence that "the Company will thrive with proper stewardship."2 Unfortunately, today, the Company's shares trade at just $0.43, a decrease of nearly 80% since most of you were appointed.3

    At the start of 2024, Chair Dr. Odysseas Kostas and then-CEO Patrick Holt issued a letter to shareholders stating their belief that "the [C]ompany is fundamentally in a much stronger position today."4 The pair also announced a share repurchase plan of up to $50 million, citing their "increasing confidence in the business, the undervalued stock price and [their] commitment to creating shareholder value." On the date of this letter, Amarin's share price closed at $1.15.5 Although the Company's shares have grown even more undervalued since this date, Amarin has not executed on the buyback.

    At $0.43/share, Amarin's market capitalization is ~$185 million, despite the Company having zero debt and a stable cash balance of nearly $300 million. Instead of fulfilling its commitment to use a mere 15% of its net cash to repurchase its undervalued common shares, the Company recently announced a 1-for-20 reverse split of its American Depositary Shares – making no mention of the previously announced buyback.6 This move does not inspire confidence, as reverse splits typically have a negative effect on a stock's future price.

    As Sarissa noted in its February 2023 presentation, perpetually running an unprofitable company is not sustainable.7 We could not agree more. The Board should immediately announce and run a strategic review process with the goal of preserving and maximizing value for all shareholders. Given the Company's net cash position of ~$0.75/share, any transaction should immediately provide shareholders at least that amount in value. Given the efforts made to date to establish a foundation for a patent-protected international business, we believe the value to shareholders could be meaningfully higher.

    While we welcome the opportunity to speak with you about the viability of this approach, we feel the Board should respond publicly given the commitments you and Sarissa have made to shareholders – both when seeking support at the 2023 General Meeting and more recently.

    Sincerely,

    Bradley Radoff and Michael Torok

    ***

    ________________________________

    1 Bloomberg. Share price as of market close on February 28, 2023, the date of the 2023 General Meeting of Shareholders.

    2 Company press release dated March 16, 2023. Link.

    3 Bloomberg. Represents the change in the Company's share price from market close on February 28, 2023 ($2.03) through market close on March 18, 2025 ($0.43).
    4 Company press release dated January 22, 2024. Link.
    5 Bloomberg. Share price as of market close on January 22, 2024, the date of the open letter.
    6 Company press release dated March 12, 2025. Link.
    7 Page 15 of Sarissa's investor presentation dated February 2, 2023. Link.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250319307992/en/

    Greg Lempel

    [email protected]

    Get the next $AMRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRN

    DatePrice TargetRatingAnalyst
    11/20/2023Underweight
    JP Morgan
    10/25/2023$3.00 → $1.00Buy → Hold
    Jefferies
    1/6/2023$1.30 → $3.00Hold → Buy
    Jefferies
    5/6/2022Neutral → Underweight
    JP Morgan
    5/5/2022$10.00 → $3.00Outperform → Mkt Perform
    SVB Leerink
    5/5/2022$10.00 → $3.00Buy → Neutral
    H.C. Wainwright
    5/4/2022Outperform → Market Perform
    Northland Capital
    2/16/2022$11.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $AMRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

    DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062 International dial in: 973-528-0011Access Code: 543818 Via online

    4/15/26 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction

    DUBLIN and BRIDGEWATER, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted the important scientific and educational activities featured at the American College of Cardiology (ACC) Scientific Sessions 2026 that emphasized elevated and high triglycerides (TG) as a contributor to residual cardiovascular (CV) risk and the role that icosapent ethyl (IPE) plays in contemporary lipid and cardiovascular risk management. Scientific dialogue across the sessions consistently reinforced that substantial residual CV risk can persist in many patients beyond lo

    4/8/26 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline

    DUBLIN and BRIDGEWATER, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology (ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline Update.i  These newly-issued, evidenced-based recommendations summarize the clinical role of icosapent ethyl (IPE) in reducing cardiovascular (CV) risk in statin-treated patients with elevated triglycerides (TG) and full

    3/18/26 8:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fishman Peter L.

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    4/2/26 4:30:11 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Berg Aaron converted options into 4,179 units of American Depositary Shares and covered exercise/tax liability with 2,298 units of American Depositary Shares, increasing direct ownership by 2% to 82,595 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    2/3/26 7:00:09 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Legal Officer Provoost Jonathan

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    2/3/26 7:00:07 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Berg Aaron bought $102,400 worth of Ordinary Shares (160,000 units at $0.64), increasing direct ownership by 25% to 805,380 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    8/5/24 5:30:03 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Holt Patrick bought $15,724 worth of Ordinary Shares (14,426 units at $1.09), increasing direct ownership by 5% to 314,426 units (SEC Form 4)

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    1/24/24 4:31:21 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    SEC Filings

    View All

    $AMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form DEF 14A filed by Amarin Corporation plc

    DEF 14A - AMARIN CORP PLC\UK (0000897448) (Filer)

    4/10/26 5:00:20 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Amarin Corporation plc

    PRE 14A - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/30/26 5:57:06 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/27/26 5:00:07 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan resumed coverage on Amarin

    JP Morgan resumed coverage of Amarin with a rating of Underweight

    11/20/23 7:16:51 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin downgraded by Jefferies with a new price target

    Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously

    10/25/23 6:25:52 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin upgraded by Jefferies with a new price target

    Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously

    1/6/23 7:26:32 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Leadership Updates

    Live Leadership Updates

    View All

    Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

    DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. "On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a beneficial addition to the board at this time," said Odysseas Kostas, MD, Chairman of the Board. "I am eager to join the board and begin working with fellow directors and the s

    4/7/25 7:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Appoints Peter Fishman Chief Financial Officer

    DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer. "Pete brings tremendous experience to his new role at Amarin, including most recently as a trusted advisor to our leadership team serving as principal financial and accounting officer for the Company," said

    12/13/24 9:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Board of Directors Announces CEO Transition

    -- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron

    6/4/24 7:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Financials

    Live finance-specific insights

    View All

    Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

    DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter 2026 financial results and conduct a conference call on Wednesday, April 29, 2026. The Company will issue a press release detailing its first quarter 2026 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062 International dial in: 973-528-0011Access Code: 543818 Via online

    4/15/26 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

    Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the fourth quarter and full year ended December 31, 20

    2/25/26 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

    DUBLIN and BRIDGEWATER, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report fourth quarter and full year 2025 financial results and conduct a conference call on Wednesday, February 25, 2026. The Company will issue a press release detailing its fourth quarter and full year 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call:Via telephone: Dial in within the United States: 888-506-0062International dial in: 973-528-0011Acces

    2/11/26 8:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amarin Corporation plc (Amendment)

    SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    12/8/23 4:26:23 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

    SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    12/5/23 7:30:10 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

    SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

    9/5/23 4:15:30 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care